3 more deaths among patients on Biogen's Aduhelm fuel safety concerns, though no link established: analyst

The death of three additional Alzheimer’s disease patients taking Biogen’s Aduhelm has heaped more concern on the safety of the controversial treatment, though it is too early to determine how the patients died.

The deaths were registered through the FDA’s adverse event reporting system, known as FAERS. Also in the database were reports of amyloid-related imaging abnormalities, or ARIA, a side effect that has been linked to the drug.